Jaguar Health stock falls 60.25 percent after FDA waiver rally
Published on 09/23/2026 at 17:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Jaguar Health stock was trading at USD 13.70 on Nasdaq on September 23, 2026 at 11:12 a.m. ET, down USD 20.76 from the previous close of USD 34.46. The 60.25 percent decline followed a sharp move linked to FDA fee waivers and a recent reverse split.
FDA waiver meets split adjustment
Access Newswire reported on September 22, 2026 that Jaguar Health received FDA fee waivers tied to Mytesi and Canalevia-CA1 for fiscal year 2027. The announcement matters because it reduces regulatory fee pressure around two products already linked to the companys commercial strategy.
Jaguar Health completed a 1-for-15 reverse stock split on September 17, 2026. In its release, Jaguar Health said the split-adjusted shares would continue trading under the JAGX symbol on Nasdaq.
Q2 revenue fell 59 percent
The latest reported quarter shows a more difficult operating picture. For Q2 2026, revenue was USD 1.225 million, compared with USD 2.979 million in Q2 2025, a 59 percent decline, according to The Globe and Mail.
The companys Q2 operating loss was USD 7.597 million, compared with USD 8.0 million in Q2 2025. Net loss reached USD 12.802 million, while operating cash flow was negative USD 5.338 million for the quarter ended June 30, 2026.
Intraday volatility remains high
Trading volume reached 7,438,068.67 shares by the September 23, 2026 quote, against an average volume of 462,361 shares. The price moved between USD 11.20 and USD 19.46 during the session, placing the intraday quote near the lower end of that spread.
Jaguar Health stock therefore combines a regulatory cost development with a much weaker Q2 revenue base. For investors, the key distinction is between lower near-term fee pressure and the companys continuing operating losses.
Jaguar Health stock data
Jaguar Health stock data
- Company: Jaguar Health, Inc.
- Ticker: JAGX
- Trading venue: Nasdaq
- Price (as of September 23, 2026 at 11:12 a.m. ET): USD 13.70
- Market capitalization: USD 5,947,277 as of September 23, 2026
- Sector / Industry: Healthcare / Biotechnology
